Basiliximab is well tolerated and effective in the treatment of @entity134 -refractory XXXX after allogeneic @entity8 .

@entity1 @entity8 @entity981 @entity2590 @entity3052 @entity1582 @entity134 @entity2132 @entity2902 @entity1893 @entity1860
Basiliximab, a chimeric @entity2902 ( @entity2902 ) antagonist, was evaluated in 17 @entity1 with @entity134 -refractory @entity2132 ( @entity2132 ) after allogeneic @entity8 ( @entity8 ). @entity1 were transplanted from a related (n = 6) or unrelated (n = 11) HLA-identical donor because of @entity981 (n = 4), @entity3052 (n = 3), @entity1860 (n = 7), @entity2590 (n = 1), @entity1893 (n = 1), and multiple @entity1582 (n = 1). Basiliximab was given at a dose of 2 x 20 mg on 2 consecutive days after @entity134 -refractory acute @entity2132 had developed. Basiliximab was repeated on day 8 in cases of persistent @entity2132 . A median of four basiliximab infusions (range 1-12) were given to these @entity1 . None had infusion-associated or cytokine-related side-effects after basiliximab. Twelve of 17 @entity1 (71%) responded to basiliximab, 9/17 (53%) had a complete response (CR) of acute @entity2132 and 3/17 (18%) had a partial response (PR). Five of 17 @entity1 (29%) did not respond. @entity2132 developed in 8/13 evaluable @entity1 and only 2/8 had responded to basiliximab before. Five of 13 evaluable @entity1 have no signs of @entity2132 and all five had a CR or PR after basiliximab. This is the first report on the safety of basiliximab in @entity1 with @entity134 -refractory acute @entity2132 . Our data suggest that basiliximab is effective in a substantial proportion of these @entity1 .
